Shares of Atara Biotherapeutics, Inc. (ATRA) are gaining about 42 percent in Thursday morning trading after the company announced a regulatory update following a recent Type A meeting with the U.S. FDA to discuss the Complete Response Letter issued for the Biologics License Application for Tabelecleucel.
The company's shares are currently trading at $7.31 on the Nasdaq, up 42.45 percent. The stock opened at $7.85 and has climbed as high as $7.89 so far in today's session. Over the past year, it has traded in a range of $3.92 to $19.15.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.